Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

P

Pieris Pharmaceuticals

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Anemia of Chronic Kidney Disease

Treatments

Biological: PRS-080-Placebo#001
Biological: PRS-080#022-DP

Study type

Interventional

Funder types

Industry

Identifiers

NCT02754167
PCS_02_15

Details and patient eligibility

About

Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for the treatment of anemia of chronic disease. This Phase Ib study shall investigate the safety, pharmacokinetics and pharmacodynamics of a single administration of PRS-080#022-DP in anemic stage 5 chronic kidney disease patients undergoing hemodialysis.

Full description

This is a multi-center, randomized, double-blind, placebo-controlled, single ascending dose phase Ib study in anemic stage 5 chronic kidney disease patients requiring hemodialysis. Eligible subjects will undergo screening assessments and PRS-080#22-DP will be administered by intravenous infusion. The study will consist of 3 dose cohorts of 2 mg/kg, 4 mg/kg, and 8 mg/kg body weight with 8 subjects in each cohort. Using a standard 6+2 design, 6 subjects in each cohort will be randomized to PRS-080#022-DP and 2 subjects in each cohort will be randomized to placebo. The decision to escalate the dose will be based on an interim analysis of clinical safety and safety laboratory data. Safety and tolerability, pharmacokinetics, pharmacodynamics as well as potential immunogenicity will be investigated.

Enrollment

24 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with stage 5 chronic kidney disease having been on hemodialysis for at least 90 days
  • Patients being on stable erythropoiesis-stimulating agent (ESA) dose
  • Hemoglobin (Hb) 9 - 11 g/dL
  • Ferritin ≥ 300 ng/mL.
  • Transferrin saturation (TSAT) ≤ 30%
  • Hepcidin 5 - 50 nmol/L

Exclusion criteria

  • Anemia due to causes other than chronic kidney disease, including hemoglobinopathies, hemolytic anemias, myelodysplasia or malignancy
  • Blood transfusion within 2 months before administration of study medication.
  • Iron treatment from 1 week before study medication administration until 1 week after study medication administration.
  • Previous enrollment in this study
  • Current or previous (within 60 days before study medication administration) treatment with another investigational drug and/or medical device or participation in another clinical study.
  • Pregnancy or breast-feeding women of child bearing age.
  • Known allergy to any component of the PRS-080#022-DP formulation
  • Positive for hepatitis B surface antigen, anti-hepatitis C virus antibody, or human immunodeficiency virus
  • Planned surgery during the study period
  • Unwilling or unable to comply with the protocol, in the judgment of the investigator
  • Unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty/stents, apoplexy or coronary artery bypass grafting <3 months prior screening.
  • Congestive heart failure: New York Heart Association Class III or IV.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

24 participants in 2 patient groups, including a placebo group

PRS-080#022-DP
Experimental group
Description:
Hepcidin antagonist, single administration, ascending doses
Treatment:
Biological: PRS-080#022-DP
PRS-080-Placebo#001
Placebo Comparator group
Description:
Comparator treatment, single administration
Treatment:
Biological: PRS-080-Placebo#001

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems